The epitope CA125 or MUC16 was originally described in 1983, is present in 95% of high grade serous ovarian cancer and is highly related to worse clinical outcomes.17,18 MUC16/CA125 is a heavily glycosylated member of the mucin protein family. This evidence concerns the gene MUC16 and ovarian serous adenocarcinoma.